Inovalon this week announced AstraZeneca would utilize the company's ONE Platform to create a value-based platform to bolster the commercialization of a new therapy for Chronic Obstructive Pulmonary Disease (COPD). According to a press release, experts under Inovalon's Avalere branch will leverage […]
PCORI Awards Grant to HFA
The Patient-Centered Outcomes Research Institute (PCORI) recently awarded the Hemophilia Federation of America (HFA) a Eugene Washington PCORI Engagement Award, Hemophilia News Today reports. PCORI chose HFA and its Females in Research Sharing and Translation (FIRST) project for the […]
NPC: Value Assessment Frameworks ‘Not Ready for Prime Time’
Despite the rising popularity of value assessment frameworks among decision makers in the health care industry, a recent analysis from the National Pharmaceutical Council (NPC) suggests they are "not ready for prime time." The analysis, which was published in Value in Health, examined how value […]
Webinar on RWE in Pharma Set for Aug. 15
An upcoming webinar set for Aug. 15 will highlight how 30 biopharmaceutical companies are incorporating or planning to utilize real-world evidence and real-world data. The webinar is set to begin 1:30 p.m. EST. Featured speakers are Mary Jo Lamberti, Tufts Center for the Study of Drug Development […]
Jansen: More Transparency Needed in Value Assessments
Open-Source Value Project Lead Scientific Advisor Jeroen Jansen in a recent interview with the American Journal of Managed Care says one key hurdle facing value assessments is a lack of transparency. " ... There's a lot of debate about what's the appropriate framework, the different ways of how to […]
NPC, AcademyHealth Webinar Available On-Demand
A June 18 webinar hosted by the National Pharmaceutical Council and AcademyHealth is now available to view on-demand. The webinar, titled "What's in a Number? It Matters in Health Policy Conversations," looks at how estimates on prescription drug spending can fluctuate anywhere between 10 percent […]
What Impact Could Preprints Have on Academic Articles?
A recent preprint on bioRxiv suggests papers posted as preprints prior to being published in peer review journals see increased citations and higher Altmetric scores than other articles, according to a Publication Plan report. According to the report, the authors of the article analyzed preprints […]
Webinar Spotlights Legislative Outlook for CER
A recent webinar hosted by the Alliance for Health Policy looks at what could be in store for comparative effectiveness research in the legislative arena. The webinar was posted on YouTube July 29. "This webinar outlined the various PCORI reauthorization bills and amendments that have been […]
Panel Discusses Creative Financing Proposals
An expert panel during the International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) meeting in New Orleans discussed a number of innovative payment models for tackling some key cost hurdles involving new, transformative therapies. The National Pharmaceutical Council (NPC) in a […]
On-Demand Webinar from NPC, NAHPC Highlights Health Spending
A July 17 webinar hosted by the National Pharmaceutical Council (NPC) and National Alliance of Healthcare Purchaser Coalitions (NAHPC) on health care spending is now available on demand. The online event, titled "It Costs How Much? Understanding Health Care Spending and Getting to the Root of the […]
Intermountain Healthcare Launching Value-Based Care Company
Intermountain Healthcare is preparing to launch a new value-based care company called Castell, according to a Managed Healthcare Executive report. The company, according to the report, will offer clients a new platform aimed at bolstering practices. "Intermountain has actively developed tools and […]
Article Spotlights Value-Based Contracting in Oncology
While value-based contracting presents an opportunity to address the high costs associated with cancer care, there are still a number of barriers which complicate adoption of those models, the authors of a recent article published on Managed Healthcare Executive write. Cancer costs, according to […]
McQeen Talks Cost Effectiveness
University of Colorado's R. Brett McQueen during a recent interview with the American Journal of Managed Care (AJMC) discussed why it's necessary to consider numerous criteria when working to determine cost effectiveness. "Taking into account not only traditional criteria, such as […]
Clinerion, Dresden International University Partner on RWE, RWD Course
Dresden International University's (DIU) Master's Program in Clinical Research and Clinerion are partnering on a new real-world evidence and real-world data initiative as part of the university's new course on real-world evidence generation. According to a press release, the collaboration will […]
Report Finds Patients are ‘Confused’ on Health Care
Although 78 percent of patients report positive health care experiences, roughly 69 percent reported feeling a lack of control of their patient journey, according to a recent report by Maestro Health. According to that report, 79 percent of patients also reported that it was too expensive to […]
Cummings Announces Plans to Get Pharma Execs to Testify on Drug Prices
Following a Friday hearing on drug prices and their impact on patients, Rep. Elijah Cummings, House Oversight and Reform Committee chairman, announced plans for a hearing in which pharmaceutical executives would be called to testify on prices, The Hill reports. "I want to tell you, this may make […]
Grassley Touts Drug Pricing Bill
Republican Sen. Chuck Grassley on Thursday sought support for his key drug pricing proposal, saying that his plan would outmatch anything produced by President Donald Trump and Democrats, STAT reports. "Who knows what he's going to do at the last minute," Grassley, chairman of the Senate Finance […]
NICE to Review Guidance Development Protocol
The U.K.'s National Institute for Health and Care Excellence (NICE) is planning to review how it develops guidance on prescription drugs, pharmaphorum reports. According to the report, NICE will cover a number of topics as part of its review, including uncertainty in evidence. "NICE is undertaking […]
Report: NHS Patient Data Could be Worth Billions
A new report from Ernst and Young suggests the U.K.'s National Health Service's (NHS) patient records could be worth billions of British pounds, pharmaphorum reports. According to the pharmaphorum report, NHS has records on some 55 million patients. "The quality and scale of NHS data, covering a […]
How Does Pharma Stay Strong in Washington?
A recent report by STAT looks at how the pharmaceutical industry, despite being the target of attacks from all sides, continues to keep its grip in Washington. To read the report, click here. (Paid subscription required) […]
PAI and BresMed Join Forces to Support Expanded Use of More Advanced Economic Modelling Software, heRo3
Policy Analysis Inc. (PAI) and BresMed, two leading health-economics and outcomes research consultancies, are pleased to announce that they are joining forces to assist biopharma companies and other life sciences organizations in expanding their use of the new cloud-based modeling platform, heRo3. […]
Evidence-based vs Consensus-based Guidelines in Clinical Practice
There exists a "fundamental misunderstanding" about the distinction between evidence-based and consensus-based guidelines in clinical practice, the authors of a recent article published on JAMA write. "In this Viewpoint, we suggest that this distinction represents a fundamental misunderstanding of […]
eyeforpharma Webinar to Talk Impact of RWE on RCTs
Real-world evidence (RWE) and how it could impact randomized clinical trials (RCTs) will take center stage during an upcoming webinar being offered by eyeforpharma. The webinar is set to begin 9:30 a.m. EST Tuesday, July 23. Panelists include: Sebastian Schneeweiss, professor of medicine and […]
ICER President Makes Case for QALY
Steven Pearson, president of the Institute for Clinical and Economic Review (ICER), in a recent commentary dives into why the quality-adjusted life year, or QALY, is a metric worth keeping. Pearson writes that clinical studies frequently measure health gains through "disease-specific measures" like […]
NPR Report Spotlights ICER
A recent report by NPR highlights the increasing influence of an organization which has been branded the "biggest threat" to big pharma: The Institute for Clinical and Economic Review (ICER). The nonprofit drug pricing watchdog has made a name for itself as it produces reports on whether a drug is […]
Infographic Spotlights Impact of Testing
Each test ordered as part of a patient's care can have an impact on how care services are delivered, according to Quest Diagnostics. Quest Diagnostics in an infographic outlines how lab tests can bolster care and support the Triple Aim. "You'll see how each test adds value to care delivery, […]
Article Proposes Key Concepts for Journal Indicators
The authors of a recent article published in Nature outline how the future of journal indicators should be designed and implemented. According to a report by The Publication Plan, the authors of the article suggest the "next generation" of indicators should, among other things, possess a set role […]
PhRMA: International Reference Pricing Carries Negative Consequences for Patients
International reference pricing and other government-mandated pricing measures carry negative consequences for the patient, a recent post by PhRMA suggests. Access to new medicines, the post states, is significantly hampered by international pricing indices. "Nearly 90% of new medicines launched […]
Report Takes Deep Dive into Machine Learning
A recent report published in Value in Health offers a high-level look at the role of machine learning for health care outcomes researchers and decision makers. The report, "Machine Learning for Health Services Researchers," spotlights a number of key topics, including estimators, an algorithm which […]
Meeting Spotlights RCTs, RWE in Regulatory Setting
View a 6-hour video of Day 1 of Duke Margolis meeting entitled "Leveraging Randomized Clinical Trials to Generate RWE for Regulatory Purposes," highlighting actual trials and case examples that have been or are in the process of being implemented for regulatory labeling. Presentations include RWE […]
